8-K: Immunome 2026 Annual Meeting Voting Results

Immunome, Inc. reports the successful election of directors and ratification of auditors at its 2026 Annual Meeting.

Summary

• The 2026 Annual Meeting of Stockholders was held on June 9, 2026.
• Stockholders elected James Boylan, Sandra Swain, M.D., and Philip Wagenheim as Class III directors until 2029.
• Ernst & Young LLP was ratified as the independent registered public accounting firm for fiscal year 2026.
• Executive compensation was approved on an advisory basis.
• Stockholders voted in favor of holding annual advisory votes on executive compensation.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing reflecting standard corporate governance outcomes with no material impact on financial strategy.

Positives

• Successful election of all proposed Class III directors.
• Strong shareholder support for the ratification of Ernst & Young LLP as auditors.
• Advisory approval of executive compensation indicates alignment between management and shareholders.
• Clear mandate from shareholders to continue annual advisory votes on executive compensation.

Negatives

• James Boylan received a significant number of withheld votes (22,171,996) compared to other director nominees.

Risks

• None identified in this filing.

Future Outlook

The company will continue to hold annual advisory votes on executive compensation as requested by shareholders.

Industry Context

StockSavvy.ai notes that this filing represents standard corporate governance procedures for a Nasdaq-listed biotechnology company, ensuring regulatory compliance and board continuity.

Comparison to Industry Standards

• The election of directors and auditor ratification are consistent with standard practices for U.S. public companies.
• The adoption of annual 'say-on-pay' votes aligns with the prevailing trend among institutional investors and public companies.

Corporate Governance

Stakeholder Impact

• Shareholders have confirmed their support for current board leadership and executive compensation structures.

Next Steps

• Hold the 2029 Annual Meeting of Stockholders for the next Class III director election cycle.
• Continue annual advisory votes on executive compensation.

Key Dates

Keywords

Immunome, IMNM, Annual Meeting, Proxy Voting, Corporate Governance, Director Election